A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors

Key Inclusion Criteria:

- Participants with histologically confirmed non-central nervous system (CNS) solid
tumor that is metastatic and for whom there is no available standard therapy.

- At least 18 years of age.

- Signed informed consent prior to any screening procedures.

- Measurable disease according to RECIST v1.1.

- Life expectancy of >3 months.

- Qualify for palliative radiotherapy as an available option for disease management.

- Eastern Cooperative Oncology Group (ECOG) 0-1.

- Normal or adequate liver, renal, cardiac and bone marrow function.

Key Exclusion Criteria:

- Prior malignancy except for non-melanoma skin cancers and in situ cancers.

- Condition contraindicating radiotherapy.

- Rapidly progressing disease.

- Active, known or suspected autoimmune disease.

- History of non-infectious pneumonitis that required steroids or currently has
pneumonitis.

- Contraindications to the use of pembrolizumab.

- Condition requiring systemic treatment with either corticosteroids or other
immunosuppressive medications within 14 days of first treatment.

- Received an allogeneic tissue/solid organ transplant.

- Active infection requiring systemic therapy.

Note: Other protocol defined inclusion and exclusion criteria may apply.